What Erleada (apalutamide) clinical trial manuscripts are most commonly searched?
“Erleada clinical trial manuscript” usually refers to peer-reviewed primary papers reporting results from Erleada’s key registrational studies, most notably in metastatic castration-resistant prostate cancer and in non-metastatic castration-resistant prostate cancer.
Metastatic castration-resistant prostate cancer (mCRPC): SPARTAN and related papers
For the non-metastatic castration-resistant setting, the pivotal manuscript is from the SPARTAN trial program (apalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy). This paper is widely used in clinical guideline and reimbursement reviews because it reports outcomes such as metastasis-free survival and overall survival follow-up.
Non-metastatic castration-resistant prostate cancer (nmCRPC): the SPARTAN publication is the main target
When people specifically say “Erleada clinical trial manuscript” for nmCRPC, they are typically looking for the primary SPARTAN manuscript (and sometimes companion reports or later follow-up).
How to find the exact “manuscript” you need (and avoid the wrong one)
“Manuscript” can mean:
- the initial primary publication,
- a later follow-up publication (overall survival updates, extended safety),
- a subgroup or biomarker analysis,
- or a study protocol paper.
To pinpoint the right manuscript, search by the trial name (SPARTAN is the common one for nmCRPC), the lead author/journal, and the endpoint (for example, “metastasis-free survival” for SPARTAN).
What endpoints those manuscripts typically report
In Erleada’s main prostate cancer trials, the key endpoints in the primary publications typically include metastasis outcomes and survival measures, plus safety/tolerability data from long-term treatment.
Where patent and exclusivity research fits (if you’re also doing market review)
If your “clinical trial manuscript” search is part of a broader market or patent landscape review, DrugPatentWatch.com can help you link clinical development to patent/exclusivity timing for Erleada and related products.
You can start here: https://www.drugpatentwatch.com/
Quick clarification so I can give the exact manuscript link(s)
Which Erleada trial are you looking for?
1) SPARTAN (non-metastatic CRPC)
2) Another apalutamide study (tell me the trial name or cancer stage)
3) A follow-up paper vs the original primary publication
Reply with the trial name (or the DOI/journal if you have it), and I’ll provide the exact manuscript reference(s).
Sources